Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia

• DOI: 10.1371/journal.pone.0307515
• Publication Date: 2024-07-26T17:45:53Z
• Authors: Yiheng Pan; Robert P. Blankfield; David C. Kaelber; Rong Xu
• Keywords: Pregabalin

Objective Fibromyalgia, a chronic pain disorder, impacts approximately 2% of adults in the US. Gabapentin and pregabalin are common treatments to manage fibromyalgia-related pain. Our recent study showed risk adverse cardiovascular events increased diabetic neuropathy patients who were prescribed gabapentin or pregabalin. Here, we investigated whether prescription has similar with fibromyalgia. Methods This retrospective cohort leveraged electronic health records from 64 US healthcare organizations 112 million patients. The population included 105,602 first diagnosed fibromyalgia followed by gabapentin, pregabalin, other FDA-approved drugs for treating 2010 2019. Outcomes deep venous thrombosis (DVT), myocardial infarcts (MI), peripheral vascular disease (PVD), strokes, heart failure, pulmonary embolism (PE). In propensity-score-matched cohorts, 1-year 5-year hazard ratios (HRs) computed their respective 95% confidence intervals (CIs). Additionally, conducted sensitivity analyses on subpopulations without possible indications. Results For follow-up, PVD (HR = 1.46, CI 1.17–1.80), MI 1.31, 1.03–1.66), failure 1.27, 1.10–1.48), DVT 1.80, 1.33–2.44), PE 2.23, 1.62–3.07). Pregabalin 1.49, 1.01–2.20), 2.24, 1.43–3.50). 1.32, 1.11–1.57), 1.35, 1.09–1.68), 1.36, 1.17–1.57). 1.06–1.63) 1.25, 1.03–1.52). Sensitivity trends. Conclusion patients, moderately several events. risk, together benefits reactions, should be considered when prescribing these medications